Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgical Oncology
Published in: Indian Journal of Surgical Oncology 1/2021

01-04-2021 | Cholecystitis | Review Article

Molecular Oncology of Gall Bladder Cancer

Authors: Arun Chaturvedi, Vijay Kumar, Sameer Gupta

Published in: Indian Journal of Surgical Oncology | Special Issue 1/2021

Login to get access

Abstract

Gall bladder carcinoma (GBC) is a worldwide problem, with a higher incidence in areas of the world where cholelithiasis is common. As GBC is usually diagnosed in an advanced stage, the mortality is high. An understanding of the molecular pathways of carcinogenesis and the mutations involved in the development and progression of GBC could be useful in early diagnosis. Understanding molecular markers of prognosis as well as predictors of outcome could also potentially benefit patients undergoing treatment. New therapies targeting major molecular pathways and immunotherapy are exciting novel therapeutic options. This review focuses on the current understanding of the molecular oncology of GBC.
Literature
1.
Are C, Ahmad H, Ravipati A, Croo D, Clarey D, Smith L, Price RR, Butte JM, Gupta S, Chaturvedi A, Chowdhury S (2017) Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol 115(5):580–590PubMed
2.
Randi G, Franceschi S, la Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118(7):1591–1602PubMed
3.
Park YK, Kim SW, Park YH (1989) A clinical study of gallbladder carcinoma. Korean J Gastroenterol 21:113–122
4.
Kimura K, Ohto M, Saisho H, Unozawa T, Tsuchiya Y, Morita M, Ebara M, Matsutani S, Okuda K (1985) Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 89:1258–1265PubMed
5.
Wistuba Ignacio I, GazdarAdi F (2004) Gallbladder cancer: lessons from a rare tumor. Nat Rev Cancer 4:695–706PubMed
6.
Sasatomi E, Tokunaga O, Miyazaki K (2000) Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepato-Biliary-Pancreat Surg 7:556–567
7.
Lazcano-Ponce EC et al (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51:349–364PubMed
8.
Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y (2000) Relation between K-rascodon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepato-Biliary-Pancreat Surg 7:198–205
9.
Roa I, de Aretxabala X, Araya JC, Roa J (2006) Preneoplastic lesions in gallbladder cancer. J Surg Oncol 93:615–623PubMed
10.
Pfeifer GP (2000) p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450:155–166PubMed
11.
Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J (1996) p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immune-histochemical study. Hum Pathol 27:360–365PubMed
12.
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53Database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614PubMed
13.
Mambo E, Gao X, Cohen Y, Guo Z, Talalay P, Sidransky D (2003) Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A 100:1838–1843PubMedPubMedCentral
14.
Tang M, Baez S, Pruyas M, Diaz A, Calvo A, Riquelme E, Wistuba II (2004) Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. Clin Cancer Res 10:1041–1046PubMed
15.
Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF (2002) Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 160:2073–2079PubMedPubMedCentral
16.
Hezel AF, Deshpande V, Zhu AX (2010) Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28:3531–3540PubMedPubMedCentral
17.
Mu DQ, Peng YS, Xu QJ et al (2004) Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 10:471–475PubMedPubMedCentral
18.
Singh MK, Chetri K, Pandey UB, Kapoor VK, Mittal B, Choudhuri G (2004) Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol 19:916–921PubMed
19.
Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y (2000) Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepato-Biliary-Pancreat Surg 7:198–205
20.
Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J (2016) Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 122:3838–3847PubMed
21.
Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520PubMedPubMedCentral
22.
Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki K (2005) Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol 12:354–363PubMed
23.
Letelier P, Brebi P, Tapia O, Roa JC (2012) DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer. Clin Epigenetics 4:11PubMedPubMedCentral
24.
Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M (2001) Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61:5562–5569PubMed
25.
Pignochino Y, Sarotto I, Peraldo-Neia C et al (2010) Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631PubMedPubMedCentral
26.
Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356–365PubMed
27.
Suzuki T, Takano Y, Kakita A, Okudaira M (1993) An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract 89:283–292
28.
Kim YW et al (2001) Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 8:1127–1132PubMed
29.
Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Schulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163:217–229PubMedPubMedCentral
30.
Ma HB, Hu HT, Di ZL et al (2005) Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. World J Gastroenterol 11(5):744–747PubMedPubMedCentral
31.
Yi S, Yang ZL, Miao X et al (2014) N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas. Pathol Res Pract 210(6):363–368PubMed
32.
Ghosh M, Kamma H, Kawamoto T et al (2005) MUC1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 31(8):891–896PubMed
33.
Churi CR, Shroff R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383PubMedPubMedCentral
34.
Letelier P, Garcia P, Leal P et al (2014) Immunohistochemical expression of vascular endothelial growth factor in advanced gallbladder carcinoma. Appl Immunohistochem Mol Morphol 22(7):530–536PubMed
35.
Kornprat P, Rehak P, Ruschoff J et al (2006) Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma: a systematic analysis including primary and corresponding metastatic tumours. J Clin Pathol 59:202–206PubMedPubMedCentral
36.
37.
Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klümpen HJ, Takkenberg RB, Wilmink H, Würdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ (2019) Crossing borders: a systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol 140:8–16PubMed
38.
Bridgewater JA, Goodman KA, Kalyan A et al (2016) Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book 35:e194–e202PubMed
39.
Mhatre S, Wang Z, Nagrani R, Badwe R, Chiplunkar S, Mittal B, Yadav S, Zhang H, Chung CC, Patil P, Chanock S, Dikshit R, Chatterjee N, Rajaraman P (2017) Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study. Lancet Oncol 18:535–544PubMed
40.
Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators (2014) Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 15:819–828PubMedPubMedCentral
41.
Chong DQ, Ax Z (2016) The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget 7(29):46750–46767PubMedPubMedCentral
42.
Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S (2018) PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wildtype patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer 92:11–19PubMed
43.
Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11:48–54PubMed
44.
Sun XN, Cao WG, Wang X, Wang Q, Gu BX, Yang QC, Hu JB, Liu H, Zheng S (2011) Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol 32:1183–1190PubMed
45.
Moehler M, Maderer A, Schimanski C (2014) Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebocontrolled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 50:3125–3135PubMed
46.
Valle JW, Wasan H, Lopes A et al (2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol 16:967–978PubMedPubMedCentral
47.
Santoro A, Gebbia V, Pressiani T et al (2015) A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the Van Gogh study. Ann Oncol 26:542–547PubMed
48.
Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36(3):276–282PubMed
49.
Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J (2018) Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci 109(1):215–222PubMed
50.
Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK (2018) Genetic landscape of gallbladder cancer: Global overview. Mutat Res 778:61–71
51.
Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003–1010PubMed
52.
Pauff JM, Goff LW (2016) Current progress in immunotherapy for the treatment of biliary cancers. J Gastrointest Cancer 47:351–357PubMed
53.
Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) (2013) Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). J Gastrointest Surg 17:1609–1617PubMed
54.
Okusaka T, Ueno M, Sato T et al (2012) Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial). J Hepatobiliary Pancreat Sci 19:314–318PubMed
55.
56.
Bang YJ, Doi T, Braud FD et al (2015) Safety and efficacy of pembrolizumab (MK-3475) in patients with advanced biliary tract cancer: Interim results of KEYNOTE-028. Eur J Cancer 51:S112
57.
Arkenau HT, Martin-Liberal J, Calvo E et al (2018) Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 23(12):1407–e 136PubMedPubMedCentral
58.
Sahai V, Griffith KA, Beg MS, Zalupski M (2018) A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer. J Clin Oncol 36(15 Suppl):TPS4142–TTPS541
Metadata
Title
Molecular Oncology of Gall Bladder Cancer
Authors
Arun Chaturvedi
Vijay Kumar
Sameer Gupta
Publication date
01-04-2021
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue Special Issue 1/2021
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-019-01008-2

Other articles of this Special Issue 1/2021

Indian Journal of Surgical Oncology 1/2021 Go to the issue

Original Article

Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies

Original Article

GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma

Original Article

Clinical and Histopathological Correlation of p16 and p53 Expression in Oral Cancer

Original Article

TRF2 Overexpression at the Surgical Resection Margin: A Potential Predictive Biomarker in Oral Squamous Cell Carcinoma for Recurrence

Review Article

microRNAs: New-Age Panacea in Cancer Therapeutics

Original Article

??-Catenin—a Possible Prognostic Molecular Marker for Recurrence in Histopathologically Negative Surgical Margin of Oral Cancer